QIAGEN Enhances Tuberculosis Testing in Children with QuantiFERON-TB Gold Plus, Welcomed by New U.S. Guidelines
QIAGEN, a leading provider of innovative molecular diagnostics solutions, has received a significant boost with the American Academy of Pediatrics (AAP) recommending the use of IGRA tests, such as QuantiFERON-TB Gold Plus, for screening children of all ages who are at risk of tuberculosis (TB) infection. This new recommendation aligns with the growing trend in U.S. tuberculosis control guidelines, emphasizing the use of modern blood-based tests to effectively combat the spread of this potentially deadly bacterial infection.
The AAP’s endorsement of IGRA tests is a significant milestone, recognizing the importance and reliability of the QuantiFERON-TB Gold Plus in diagnosing TB infections in children. This advanced test detects the immune response to Mycobacterium tuberculosis, the bacterium causing TB, and provides accurate results within 24-48 hours. With this endorsement, pediatricians and other healthcare professionals can now confidently diagnose and treat TB in children, ensuring early intervention and preventing the further spread of this infectious disease.
Tuberculosis remains a major global health concern, particularly in developing countries, with children being one of the most vulnerable populations. Traditionally, diagnosing TB in children has been challenging due to the limited efficacy of conventional tests and the difficulties associated with obtaining appropriate specimens from young patients. However, with the availability of QuantiFERON-TB Gold Plus, healthcare providers now have a reliable tool that significantly improves their ability to detect TB in children, leading to timely treatment and better disease management.
QIAGEN’s commitment to sustainability has also been highlighted in its 2023 sustainability report, demonstrating its dedication to environmental, social, and governance (ESG) goals. The company has successfully reduced Scope 1 and 2 emissions by 15% through green energy procurement, contributing to a healthier planet. Additionally, QIAGEN has decreased plastic usage by 7%, showcasing its responsibility in minimizing environmental impact.
Furthermore, QIAGEN recognizes the importance of social responsibility, leveraging partnerships to expand diagnostic access worldwide. The company has set an ambitious goal of having at least 40% women in leadership positions by 2027, promoting gender equality and diversity within the organization.
In terms of governance, QIAGEN has established a new Supplier Code of Conduct and Human Rights Committee, reinforcing ethical standards across its supply chain. These initiatives aim to ensure that QIAGEN’s values align with its business practices, fostering transparency and integrity throughout its operations.
On the innovation front, QIAGEN has launched the QIAcuity digital PCR assays for microbial applications, providing researchers with a powerful tool for infectious disease research and surveillance. With 35 new wet-lab tested digital PCR Microbial DNA Detection Assays, this technology enables precise and sensitive detection of pathogens, catering to a wide range of diseases such as tropical diseases, sexually transmitted infections, and urinary tract infections. These new assays significantly contribute to QIAGEN’s comprehensive portfolio for microbial research, which was displayed at the ASM Microbe conference from June 13-17.
In conclusion, QIAGEN’s QuantiFERON-TB Gold Plus has garnered further recognition with the AAP’s endorsement, bringing significant benefits to the screening and diagnosis of tuberculosis in children. With the support of modern blood-based tests, healthcare professionals can now better combat the spread of this infectious disease and provide early intervention for affected children. QIAGEN’s dedication to sustainability goals and innovative solutions such as the QIAcuity digital PCR assays further solidify its position as a global leader in molecular diagnostics.
Comments